5/9
08:12 am
fulc
Fulcrum Therapeutics to Participate in Upcoming May Conferences [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics to Participate in Upcoming May Conferences [Yahoo! Finance]
5/9
08:00 am
fulc
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Low
Report
Fulcrum Therapeutics to Participate in Upcoming May Conferences
5/8
08:21 am
fulc
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology [Yahoo! Finance]
5/8
08:00 am
fulc
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Low
Report
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
5/6
08:00 am
fulc
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
Medium
Report
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
3/28
04:05 pm
fulc
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
Low
Report
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
3/22
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/18
07:09 am
fulc
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
High
Report
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
3/18
07:00 am
fulc
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
High
Report
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
3/13
08:15 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $14.00 price target on the stock.
Low
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $14.00 price target on the stock.
3/8
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/7
06:57 am
fulc
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock [Yahoo! Finance]
Low
Report
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock [Yahoo! Finance]
3/6
12:17 pm
fulc
Fulcrum hits 52-week high as CEO buys shares [Seeking Alpha]
Medium
Report
Fulcrum hits 52-week high as CEO buys shares [Seeking Alpha]
3/5
08:00 am
fulc
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
Medium
Report
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
2/28
02:42 pm
fulc
Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Neutral
Report
Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
2/28
02:29 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target raised by analysts at HC Wainwright from $14.00 to $17.00. They now have a "buy" rating on the stock.
Low
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target raised by analysts at HC Wainwright from $14.00 to $17.00. They now have a "buy" rating on the stock.
2/28
10:57 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target raised by analysts at Piper Sandler from $13.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target raised by analysts at Piper Sandler from $13.00 to $15.00. They now have an "overweight" rating on the stock.
2/27
07:38 am
fulc
Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
2/27
07:12 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 [Yahoo! Finance]
2/27
07:00 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
Medium
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
2/20
04:01 pm
fulc
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
Low
Report
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
2/11
07:20 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after 31% loss over the past year [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after 31% loss over the past year [Yahoo! Finance]